Both Novo Nordisk and Eli Lilly have invested heavily in expanding manufacturing infrastructure for oral GLP-1 therapies, including facilities across North Carolina, Texas, Alabama, and Puerto Rico
Cost, patient preference, and side effects still matter, but they are all secondary to what the insurance will actually pay for. Zepbound is for adults with obesity or overweight who also have weight-related health conditions such as type 2 diabetes, cardiovascular disease, or high blood pressure
Remarkably, every patient who received the highest dose of retatrutide experienced a weight loss of at least 5% of their body weight after 48 weeks of treatment
However, its important to use them cautiously if youre experiencing gastrointestinal side effects from Mounjaro like nausea or constipation
Bibliography GLP-1 agonists: Diabetes drugs and weight loss
Children: Do not use